Deals
Apogee’s pipeline in a product drug zumilokibart achieved significant disease clearance in a mid-stage atopic dermatitis trial, but investors were miffed by a royalty financing deal with Blackstone.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Investors are salivating at the possibility of a hot merger-and-acquisition market in 2018.
Shares of Strata Skin Sciences are up more than 12 percent this morning after the company announced it will explore strategic options up to and including a sale of the company in order to enhance stockholder value.
Perrigo is expected to face competition from Swiss food giant Nestle and the private equity owners of German drug firm Stada.
As part of a portfolio update, Altas Ventures noted that Raze Therapeutics, a biotech launched in 2014, has closed its doors.
Harpoon’s former CEO also hinted at possible growth at the office, including new hires for engineering and clinical team members.
A look at what three ex-Genentech employees have accomplished at Denali so far.
Gilead was interested in Cell Design Labs for its technology around bi-specific antigen recognition and its “Throttle” technology.
This year wasn’t big for mergers and acquisitions in biopharma, particularly compared to 2015 and 2016.
As Sanofi grapples with the fallout from its Dengue vaccine, the termination of its late-stage C. diff vaccine and falling short of its third quarter expectations, company investors are getting antsy for some good news.
Dart will close its doors on Feb. 9 due to poor progress on its therapeutic goals and little return on hundreds of millions of dollars in R&D.